Abstract: A composition of matter is used as an ingredient in consumable products (for humans and pets) comprising at least 0.005% by weight and preferably 1-30% by weight of highly refined cellulose fiber having at least 15% by total weight of the highly refined cellulose material of an oil-based flavoring or aroma-producing material, the composition of matter being provided as a free-flowing, dry-feel particulate material having a number average mean particle size of less than 2 mm.

Abstract: The invention provides liquid formulation compositions and medicament delivery devices, and methods for preparing and using the same. For example, the liquid formulation composition is an emulsion including a solvent and liquid particles, which includes surfactants and are dispersed in the solvent. The volume average particle size of the liquid particles is less than about 100 ?m; the surface tension of the liquid formulation composition is less than about 60 mN/m; and the absolute value of zeta potential is greater than about 15 mV. The containment vessel may be a sprayer or a dropping device. The invention also provides methods for preparation of the liquid formulation compositions and medicament delivery devices as well as methods for using the same in treatment of various diseases and condition, for example, otitis media, otitis externa, rhinitis, sinusitis, lower respiratory tract inflammation, xerostomia (dry mouth), xerophthalmia (dry eyes) and xeromycteria (dry nose).

Abstract: It is an object of the present invention to provide an agricultural and horticultural fungicide composition that exhibits an excellent control effect on plant diseases even in a small dose and causes no fear of phytotoxicity to useful plants. The agricultural and horticultural fungicide composition of the present invention comprises at least one compound A selected from the group consisting of a compound of formula (1) {wherein each X independently is a halogeno group or a C1-6 alkyl group; n is the number of X and is any integer of 0 to 5; X? is a halogeno group; R1, R2 and R3 each independently are a C1-6 alkyl group, a C1-6 alkoxy group or a hydroxyl group; and A1 and A2 each independently are a nitrogen atom or a carbon atom}, and the like, and at least one compound B selected from the group consisting of silthiofam, an antibiotic, propineb and chinomethionat.

Abstract: A method of protecting the internal protein of hair from damage by ultraviolet light, comprising the step of applying, to the hair, a hair treatment composition comprising a lactone, a disaccharide, an inorganic salt and an organic acid or salt thereof, having a pH in the range of from 3 to 6.5 prior to the application of an ultraviolet light to the hair, and a use of such a hair treatment composition, in the treatment of hair, to protect hair from damage by ultraviolet light.

Abstract: A carbon-polymer complex is provided and includes a porous carbon material and a binder, wherein the porous carbon material includes a material obtained from carbonization of a raw material including rice husk, the raw material having a silicon content of at least 5 wt %, the raw material is heat treated before carbonization, and the raw material is treated by an alkali treatment after carbonization to reduce the silicon content, the porous carbon material having a specific surface area of at least 10 m2/g as measured by the nitrogen BET method, a pore volume of at least 0.1 cm3/g as measured by the BJH method and MP method, and an R value of 1.5 or greater, wherein the porous carbon material includes mesopores having pore sizes from 2 nm to 50 nm and obtained from the alkali treatment of the raw material after carbonization, the porous carbon material further includes macropores and micropores.

Abstract: Keratin protein cosmetic compositions are provided that include at least one keratin protein derived from human hair and a base cosmetic solution. Methods of treatment are also provided.

Abstract: Methods for disinfecting a surface are provided which include contacting a surface with a solution comprising Fe(VI)O42?, thereby disinfecting the surfaces. In some cases, the surface to be contacted with the solution is in a space suitable for human occupancy and the surface is arranged in the ambient of the space. In addition, solutions comprising Fe(VI)O42? are provided. The solutions may additionally include a hypohalite salt and a surfactant.

Abstract: Described herein is a method for forming multi-layer drug dosage forms having at least two layers. In the method, a first formulation comprising a non-gelling matrix forming agent and having a first density is dosed into a preformed mold. A second formulation comprising a non-gelling matrix former and having a second density not equal to the first density is subsequently dosed into the preformed mold. Then, the combination of the formulations dosed into the mold is freeze dried to form the multi-layer dosage form having at least two layers. The use of a density difference between the first and second formulations ensures formation of a product with two distinct layers.

Abstract: The present disclosure relates to a stable, reproducible and bioequivalent apixaban compositions, wherein the composition comprising apixaban having a D90 particle size of more than 100 microns, preferably between 300 and 1000 microns, and more preferably between 350 and 800 microns, and further comprising one or more pharmaceutically acceptable excipients. The present disclosure further provides a process for preparation of a pharmaceutical composition comprising apixaban by wet granulation.

Abstract: A bilayer composition for amelioriation of, or prophylaxis against, SARS-CoV-2 infection comprising a: (i) a first layer consisting of 250 mg to 1600 mg of 5-aminolevulinic acid (ALA), or salt thereof, and pharmaceutically acceptable excipients that allow for immediate release of the 5-aminolevulinic acid; (ii) a second layer consisting of hydroxychloroquine (HCQ), and/or a salt thereof, in a dose of 100 mg-1500 mg, or salt thereof, and at least one pharmaceutically acceptable excipient comprising a release modifier for sustained release of the hydroxychloroquine or chloroquine.

Abstract: Disinfecting compositions containing hypochlorous acid and acetic acid are useful for treating biofilms in or on tissue, including biofilms related to wounds or other skin trauma. The compositions are useful for treating a variety of types of tissue, both on the surface on beneath the surface of tissue. Compositions are provided having various concentrations for different tissue types and infection levels. Compositions may be provided in gel form, and may include nanoparticle encapsulated molecules for controlled release.

Abstract: A capsule delivery system. The system has a first capsule containing a first capsule wall encapsulating a first active material and a second capsule containing a second capsule wall encapsulating a second active material. The first and second capsules differ in their wall materials, amounts of wall materials, ratios of wall materials, core modifiers, scavengers, active materials, curing temperatures, heating rates, curing times, or a combination thereof. Also provided is a consumer product containing this capsule delivery system.

Abstract: A hair conditioner composition with a gel network that can contain a fatty alcohol and a cationic surfactant having a chloride counterion. The gel network composition can contain a uniform lamellar structure that comprises all vesicles or mostly vesicles.

Abstract: The present invention relates in part to novel drug delivery particles comprising an anionic polymer matrix and a cationic polymer, wherein the anionic polymer matrix and cationic polymer together form drug delivery particles bound by electrostatic interactions and wherein the drug delivery particles comprise at least one biologically active agent. The invention also relates in part to a method of treating a mycobacterial infection using said drug delivery particles, and a method of making said drug delivery particles.

Abstract: The present disclosure relates to anhydrous cosmetic compositions comprising: a) From about 0.1% to about 2% of one silica silylate; b) From about 0.1% to about 5% of allantoin; c) From about 0.1% to about 5% of at least one fatty substance; d) From about 2% to about 30% of at least one emulsifier; e) From about 20% to about 30% of at least a first silicone having a viscosity from about between 2 cst to about 70 cst; and f) From about 50% to about 95% of at least a second silicone; wherein all weight percentages are based on the total weight of the cosmetic composition.

Abstract: To improve the fact that the main components of conventional deodorizing and antimicrobial agents are existing components, the effect and efficacy of which are known to some extent, and do not generate an effect better than predicted. The deodorizing and antimicrobial agent of the present invention has a loquat seed extract including non-volatile fatty acids and at least benzaldehyde and benzoic acid as a main raw material.

Abstract: The present disclosure provides methods and compositions for the treatment of oral lesions in a subject comprising a methylene blue oral rinse.

Abstract: The present invention relates generally to therapeutic articles comprised of carbonaceous blend textile materials comprising yarns having about 25 to 100 weight % carbonaceous fiber and about 0 to 75 weight % fiber made of polyester, nylon, rayon, lyocell, cellulose, wool, silk, linen, bamboo, m-aramid, p-aramid, modacrylic, novoloid, melamine, regenerated cellulose, polyvinyl chloride, antistatic fiber, poly(p-phenylene benzobisoxazole) (PBO), polybenzimidazole (PBI), polysulphonamide (PSA), and combinations thereof, or other fibers not listed that are capable of being made into yarn and textile fabrics that are knit, woven, or nonwoven, and wherein the fabric has a weight from about 3 oz/yd2 to about 20 oz/yd2.

Abstract: The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to a particular 1-di-alkyl-phosphinoyl-alkane, 1-(Diisopropyl-phosphinoyl)-nonane, referred to herein as “DIPA-1-9”. Surprisingly and unexpectedly, DIPA-1-9, is able to selectively treat (e.g., suppress) sensory discomfort arising from the lumenal epithelial lining of the pharynx and esophagus without side effects. Compared to structurally similar compounds, DIPA-1-9 did not have the problems of painful cold, stinging, or irritancy, or of adverse taste when applied in the oral cavity. To deliver the DIPA-1-9 to the lumenal epithelium of the pharynx and esophagus, an ideal formulation for delivery is a solution of DIPA-1-9 in syrup, at a concentration of 5 to 12 mg/mL and a delivery volume of less than 1 mL. The delivery unit can be a plastic vial with a design such that the syrup is poured onto the base of the tongue, next to the pillars of fauces.

Abstract: The disclosure relates to nail varnish compositions including, in one or more cosmetically acceptable organic solvents: a main film-forming agent including nitrocellulose, at least one fumed silica having a BET specific surface area of at least 170 m2/g, at least one secondary resin having at least one aromatic group in its chemical structure, at least one plasticiser, at least one colorant, which is insoluble in the solvent. The composition is free or substantially free of clay compounds, especially of modified clays, in particular of organophilic clays. The disclosure also relates to the use of these compositions for protecting and/or making up the nails, and also to packaged, ready-to-use items intended for this use.